The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion)
The Russian Federation is among countries with high cardiovascular risk. Hypercholesterolemia is a leading risk factor for the development of atherosclerotic cardiovascular diseases. To achieve low-density lipoprotein cholesterol (LDL-C) targets, such approaches as lifestyle changes and pharmacologi...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2020-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2135 |
| _version_ | 1797232070069583872 |
|---|---|
| author | M. V. Ezhov A. Catapano C. Escobar V. V. Kukharchuk M. I. Voevoda O. M. Drapkina S. A. Shalnova A. V. Starodubova V. S. Gurevich I. I. Shaposhnik O. O. Bolshakova O. S. Oynotkinova A. S. Alieva |
| author_facet | M. V. Ezhov A. Catapano C. Escobar V. V. Kukharchuk M. I. Voevoda O. M. Drapkina S. A. Shalnova A. V. Starodubova V. S. Gurevich I. I. Shaposhnik O. O. Bolshakova O. S. Oynotkinova A. S. Alieva |
| author_sort | M. V. Ezhov |
| collection | DOAJ |
| description | The Russian Federation is among countries with high cardiovascular risk. Hypercholesterolemia is a leading risk factor for the development of atherosclerotic cardiovascular diseases. To achieve low-density lipoprotein cholesterol (LDL-C) targets, such approaches as lifestyle changes and pharmacological correction, based on the use of statins, are applied. At the same time, a significant proportion of the population has moderate hypercholesterolemia and is characterized by low or moderate cardiovascular risk. Although first-line recommendations should be followed, a healthy lifestyle alone is not enough to achieve target levels of LDL-C, which means that even people with low to moderate risk may end up with the prospect of lifelong therapy with lipid-lowering drugs. These individuals do not have an indication for lipid-lowering therapy, and they are usually recommended a change in diet and supplementation. Innovative nutritional strategies have been developed to manage dyslipidemia. They were based either on changing some “risky” food components or on encouraging the consumption of “healthy” functional foods and/or nutraceuticals. Nutraceuticals (registered as food supplements in Russia) is an innovative way to help control LDL-C at low and moderate risk individuals without lipid-lowering drugs and as nutritive support for the cholesterol-lowering diet. Red yeast rice (RYR) based preparations have been already developed and available at the moment. RYR based preparations can be considered in patients with low and moderate cardiovascular risk, who have not reached the target level of LDL-C and have no indications for statin therapy or have statin intolerance. RYR based preparations contains a statin-like substance monacolin K in a dose of 3 mg. In randomized clinical trials, it was proved that the use of high-quality RYR nutraceutical leads to a decrease in LDL-C by an average of 20% without increasing the risk of side effects like for statins. Evaluation of dietary supplements and functional foods should necessarily include not only evidence of beneficial effects with respect to effects on the lipid profile and atherosclerosis, but also proven good tolerability. The manufacturing standard for these products is also important, guaranteeing component standardization and quality. RYR analogues should guarantee the absence of mycotoxin in their composition. In Russia, programs are needed for the primary prevention of atherosclerotic cardiovascular diseases with effects on hypercholesterolemia at the population level. |
| first_indexed | 2024-03-08T14:00:47Z |
| format | Article |
| id | doaj.art-1698506194ca40bebb52861a39b1fddf |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:54:25Z |
| publishDate | 2020-03-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-1698506194ca40bebb52861a39b1fddf2024-04-01T07:43:39ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532020-03-0116114715510.20996/1819-6446-2020-02-041711The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion)M. V. Ezhov0A. Catapano1C. Escobar2V. V. Kukharchuk3M. I. Voevoda4O. M. Drapkina5S. A. Shalnova6A. V. Starodubova7V. S. Gurevich8I. I. Shaposhnik9O. O. Bolshakova10O. S. Oynotkinova11A. S. Alieva12National Medical Research Center of CardiologyUniversity of MilanUniversity Hospital La PazNational Medical Research Center of CardiologyFederal Research Center, Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Institute of Internal and Preventive MedicineNational Medical Research Center for Preventive MedicineNational Medical Research Center for Preventive MedicineNational Research Center of Nutrition, Biotechnology and Food SafetySt. Petersburg State UniversitySouth-Ural State Medical University; City Clinical Hospital №1Almazov National Medical Research CenterPirogov Russian National Research Medical UniversityAlmazov National Medical Research CenterThe Russian Federation is among countries with high cardiovascular risk. Hypercholesterolemia is a leading risk factor for the development of atherosclerotic cardiovascular diseases. To achieve low-density lipoprotein cholesterol (LDL-C) targets, such approaches as lifestyle changes and pharmacological correction, based on the use of statins, are applied. At the same time, a significant proportion of the population has moderate hypercholesterolemia and is characterized by low or moderate cardiovascular risk. Although first-line recommendations should be followed, a healthy lifestyle alone is not enough to achieve target levels of LDL-C, which means that even people with low to moderate risk may end up with the prospect of lifelong therapy with lipid-lowering drugs. These individuals do not have an indication for lipid-lowering therapy, and they are usually recommended a change in diet and supplementation. Innovative nutritional strategies have been developed to manage dyslipidemia. They were based either on changing some “risky” food components or on encouraging the consumption of “healthy” functional foods and/or nutraceuticals. Nutraceuticals (registered as food supplements in Russia) is an innovative way to help control LDL-C at low and moderate risk individuals without lipid-lowering drugs and as nutritive support for the cholesterol-lowering diet. Red yeast rice (RYR) based preparations have been already developed and available at the moment. RYR based preparations can be considered in patients with low and moderate cardiovascular risk, who have not reached the target level of LDL-C and have no indications for statin therapy or have statin intolerance. RYR based preparations contains a statin-like substance monacolin K in a dose of 3 mg. In randomized clinical trials, it was proved that the use of high-quality RYR nutraceutical leads to a decrease in LDL-C by an average of 20% without increasing the risk of side effects like for statins. Evaluation of dietary supplements and functional foods should necessarily include not only evidence of beneficial effects with respect to effects on the lipid profile and atherosclerosis, but also proven good tolerability. The manufacturing standard for these products is also important, guaranteeing component standardization and quality. RYR analogues should guarantee the absence of mycotoxin in their composition. In Russia, programs are needed for the primary prevention of atherosclerotic cardiovascular diseases with effects on hypercholesterolemia at the population level.https://www.rpcardio.online/jour/article/view/2135red yeast ricehypercholesterolemiadyslipidemialow and moderate cardiovascular risk |
| spellingShingle | M. V. Ezhov A. Catapano C. Escobar V. V. Kukharchuk M. I. Voevoda O. M. Drapkina S. A. Shalnova A. V. Starodubova V. S. Gurevich I. I. Shaposhnik O. O. Bolshakova O. S. Oynotkinova A. S. Alieva The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion) Рациональная фармакотерапия в кардиологии red yeast rice hypercholesterolemia dyslipidemia low and moderate cardiovascular risk |
| title | The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion) |
| title_full | The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion) |
| title_fullStr | The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion) |
| title_full_unstemmed | The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion) |
| title_short | The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion) |
| title_sort | role of red yeast rice based preparations for non pharmacological correction of dyslipidemia in patients with low and moderate cardiovascular risk expert opinion |
| topic | red yeast rice hypercholesterolemia dyslipidemia low and moderate cardiovascular risk |
| url | https://www.rpcardio.online/jour/article/view/2135 |
| work_keys_str_mv | AT mvezhov theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT acatapano theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT cescobar theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT vvkukharchuk theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT mivoevoda theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT omdrapkina theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT sashalnova theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT avstarodubova theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT vsgurevich theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT iishaposhnik theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT oobolshakova theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT osoynotkinova theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT asalieva theroleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT mvezhov roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT acatapano roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT cescobar roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT vvkukharchuk roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT mivoevoda roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT omdrapkina roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT sashalnova roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT avstarodubova roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT vsgurevich roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT iishaposhnik roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT oobolshakova roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT osoynotkinova roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion AT asalieva roleofredyeastricebasedpreparationsfornonpharmacologicalcorrectionofdyslipidemiainpatientswithlowandmoderatecardiovascularriskexpertopinion |